Business- Page 67

BERKELEY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU) today announced that vispa-cel and CB-011 clinical abstracts have been accepted for two oral presentations and one poster presentation

The Remitly Global Card is the world’s first card that allows its users to text money and send money within the U.S. and to 175 countries, across 5 billion bank, cash, and

West Palm Beach, Fla. and Calgary, Alberta, Nov. 04, 2026 (GLOBE NEWSWIRE) — FingerMotion, Inc. (Nasdaq: FNGR) (“FingerMotion” or the “Company”) today announced that Brooks Campus No. 1 Inc., its wholly owned

Advances progress towards planned uplisting to National Securities Exchange CAMARILLO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) — Qualstar Corp. (OTC: QBAK), a custom designer and one-stop provider of enterprise archival data storage

First interim results from pivotal Phase 2/3 trial highlight encouraging remission rates in patients with relapsed or refractory AML HOUSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin”

BEACON Trial Results Selected for Official ASH Press Program Initial Patient-Reported Outcomes Demonstrate Early and Sustained Improvements in Physical Function, Pain, Fatigue, Emotional and Social Well-Being and Symptom Severity U.S. Biologics License

New analyses further characterize the clinical activity and approved dosing regimen of RYTELO® (imetelstat) in lower-risk MDS FOSTER CITY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) — Geron Corporation (Nasdaq: GERN), a hematology-focused

Verizon Powers the 2026 NFL Season with Stadium Upgrades and Global Private Wireless Network At a Glance Connected Officiating: Officials use league-issued connected watches powered by Verizon’s private wireless network to receive

— Building on previously presented DMR-001 preclinical data in Type 1 and Type 2 CALR mutations,new data to highlight strong activity against additional non-Type 1 mutations — — Trial-in-progress presentation to highlight

Updated CLOVER WaM Phase 2b analyses show durable responses in heavily pretreated patients and suggest greater benefit when used earlier in treatment paradigm Company to present Phase 3 trial-in-progress design as site